-
Most Recent
Healthcare Stocks
Healthcare encompasses a wide range of organized services to prevent, treat, and diagnose medical needs and mental illnesses. The $336 billion market is expected to grow at a compound annual growth rate of 8% until 2030, demonstrating the necessity of adequate healthcare. Healthcare companies, ranging from retailer CVS to insurance giant UnitedHealth, provide these services to a massive customer base.
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions.
7 Dependable Dividend Stocks for Long-Term Income
Explore the best dividend stocks for long-term income excelling in the healthcare, retail, tobacco and home improvement markets.
3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct
These are the pharmaceutical stocks to buy as they represent undervalued companies with a deep clinical pipeline that will support growth.
Other industries you might be interested in
Recent Healthcare Stocks Articles
Bristol-Myers, AstraZeneca Diabetes Drug Gets New Hope
Cleveland Clinic's positive review revitalizes Bristol-Myers, AstraZeneca's dapagliflozin, an experimental drug taking on a growing diabetes management market.
Sanofi Relies on Shopping to Offset Patent Losses on Key Drugs
French drug giant Sanofi (SNY) is counting on mergers and acquisitions to restore profit growth amid a slew of patent expirations.
Pfizer Pushes to Keep Lipitor Profits Flowing
Efforts to preserve the lucrative cholesterol-drug's franchise have sparked an antitrust suit. But competition is inevitable.
10 Companies Increasing Dividends
Merck and ADP top the list of stocks increasing dividends this week. See eight other companies making shareholders smile.
Amylin Stumbles After Lilly Pulls Partnership Plug
As Eli Lilly looks elsewhere for a diabetes drug partner, Amylin Pharmaceuticals stumbles. But Lilly is happy as can be. Here's why.
Hepatitis C Drug Progress Puts Several Companies on Acquisition Watch
With their hepatitis C drugs showing promise in trials, these drug makers have become attractive targets for bigger pharma players.
Pharma Firms Duke It Out — Monday’s IP Market Recap
Pharmasset (VRUS) and Inhibitex (INHX) jump on positive hepatitis C drug news, and Vertex (VRTX) stock gets knocked back.
3 Reasons Why Alexion Is the Real Deal
Alexion's fundamentals and strength in a narrow category of drugs called biopharmaceuticals make ALXN a promising stock.
Medivation Shares Shoot Up on Prostate Cancer Treatment News
Medivation (MDVN) gains almost 140% Thursday on encouraging results for its prostate cancer treatment, and Dendreon (DNDN) is further battered.
Why Dendreon Is Aiming Prostate Drug Pitches to Consumers
Dendreon (DNDN) appears to be pulling out all the stops in an effort to restore at least some of the luster to its prostate cancer treatment Provenge.
Jump Into Walgreen on the Cheap; Ditch CVS
Walgreens (WAG) might actually benefit from a breakup with Express Scripts, and its standing as a Dividend Aristocrat doesn't hurt its case, either.
Top 5 Blue-Chip Stocks to Buy
There are two great sectors to play now -- and these are their finest blue-chip offerings. Pick up these shares before it's too late.
How to Cash In on 7 Billion Humans
More people means more demand for resources and services -- it's that simple. Here are seven stocks that stand to benefit.
Amgen Bids for a Return to Favor
Amgen's (AMGN) third-quarter earnings, budget management and full-year outlook turn positive, boosting the company's market prospects.
Take the Cure — Sell J&J, Buy GSK
Johnson & Johnson and GlaxoSmithKline both have solid balance sheets, but GSK is poised to outperform its competitor.
9 Recession-Proof Biotech Stocks To Cure What Ails You
Health care stocks stay firm during a down economy and investors should consider up-and-coming biotech stocks like Alexion, Alkermes, Biogen and Cepheid.
Cigna Deal Signals More Insurance Buyouts to Come
Smaller insurers are catching attention in the wake of expected consolidation.
Should You Buy the Dow — Pfizer
Pfizer's financials are decent, as is its lineup of drugs and personal care products, but the stock is fully valued.
